{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:10:37Z","timestamp":1777356637708,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T00:00:00Z","timestamp":1219708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1038\/ncpneph0915","type":"journal-article","created":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T11:33:55Z","timestamp":1219750435000},"page":"550-559","source":"Crossref","is-referenced-by-count":35,"title":["Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price?"],"prefix":"10.1038","volume":"4","author":[{"given":"David","family":"Philibert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cattran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,26]]},"reference":[{"key":"BFncpneph0915_CR1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","volume":"310","author":"C Ponticelli","year":"1984","unstructured":"Ponticelli C et al. (1984) Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 310: 946\u2013950","journal-title":"N Engl J Med"},{"key":"BFncpneph0915_CR2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S et al. (2004) Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 66: 1199\u20131205","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0272-6386(99)70138-1","volume":"33","author":"BJ Laluck Jr","year":"1999","unstructured":"Laluck BJ Jr and Cattran DC (1999) Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis 33: 1026\u20131032","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"BFncpneph0915_CR4","first-page":"85","volume":"7","author":"C Ponticelli","year":"1992","unstructured":"Ponticelli C et al. (1992) Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 7 (Suppl 1): 85\u201390","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0915_CR5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.ki.5000289","volume":"69","author":"S Troyanov","year":"2006","unstructured":"Troyanov S et al. (2006) Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 69: 1641\u20131648","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0002-9343(79)90486-8","volume":"66","author":"LH Noel","year":"1979","unstructured":"Noel LH et al. (1979) Long-term prognosis of idiopathic membranous glomerulonephritis: study of 116 untreated patients. Am J Med 66: 82\u201390","journal-title":"Am J Med"},{"key":"BFncpneph0915_CR7","first-page":"73","volume":"2","author":"P Zucchelli","year":"1987","unstructured":"Zucchelli P et al. (1987) Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 2: 73\u201378","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0915_CR8","first-page":"793","volume":"60","author":"R MacTier","year":"1986","unstructured":"MacTier R et al. (1986) The natural history of membranous nephropathy in the West of Scotland. Q J Med 60: 793\u2013802","journal-title":"Q J Med"},{"key":"BFncpneph0915_CR9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1046\/j.1523-1755.1999.00598.x","volume":"56","author":"BE Marx","year":"1999","unstructured":"Marx BE and Marx M (1999) Prediction in idiopathic membranous nephropathy. Kidney Int 56: 666\u2013673","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS et al. (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659\u2013663","journal-title":"Arch Intern Med"},{"key":"BFncpneph0915_CR11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/sj.ki.5000058","volume":"69","author":"BO Eriksen","year":"2006","unstructured":"Eriksen BO and Ingebretsen OC (2006) The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 69: 375\u2013382","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","volume":"9","author":"C Ponticelli","year":"1998","unstructured":"Ponticelli C et al. (1998) A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444\u2013450","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR13","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V et al. (2007) A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899\u20131904","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1191\/0961203305lu2060oa","volume":"14","author":"FA Houssiau","year":"2005","unstructured":"Houssiau FA (2005) Cyclophosphamide in lupus nephritis. Lupus 14: 53\u201358","journal-title":"Lupus"},{"key":"BFncpneph0915_CR15","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou M et al. (2008) Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100\u2013105","journal-title":"J Rheumatol"},{"key":"BFncpneph0915_CR16","first-page":"1","volume":"56","author":"AJ Branten","year":"2001","unstructured":"Branten AJ and Wetzels JF (2001) Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency: study group. Clin Nephrol 56: 1\u20139","journal-title":"Clin Nephrol"},{"key":"BFncpneph0915_CR17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/ndt\/gfh312","volume":"19","author":"PW du Buf-Vereijken","year":"2004","unstructured":"du Buf-Vereijken PW and Wetzels JF (2004) Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 19: 2036\u20132043","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0915_CR18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","volume":"43","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller E et al. (2000) An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43: 1021\u20131032","journal-title":"Arthritis Rheum"},{"key":"BFncpneph0915_CR19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KW Westman","year":"1998","unstructured":"Westman KW et al. (1998) Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 9: 842\u2013852","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","volume":"119","author":"DT Boumpas","year":"1993","unstructured":"Boumpas DT et al. (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119: 366\u2013369","journal-title":"Ann Intern Med"},{"key":"BFncpneph0915_CR21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1","volume":"41","author":"CC Mok","year":"1998","unstructured":"Mok CC et al. (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41: 831\u2013837","journal-title":"Arthritis Rheum"},{"key":"BFncpneph0915_CR22","first-page":"2571","volume":"29","author":"DL Huong","year":"2002","unstructured":"Huong DL et al. (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide: a study in 84 patients. J Rheumatol 29: 2571\u20132576","journal-title":"J Rheumatol"},{"key":"BFncpneph0915_CR23","first-page":"2129","volume":"29","author":"JP Ioannidis","year":"2002","unstructured":"Ioannidis JP et al. (2002) Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 29: 2129\u20132135","journal-title":"J Rheumatol"},{"key":"BFncpneph0915_CR24","doi-asserted-by":"crossref","first-page":"355.e25","DOI":"10.1016\/j.amjmed.2005.08.045","volume":"119","author":"CC Mok","year":"2006","unstructured":"Mok CC et al. (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119: 355.e25\u2013355.e33","journal-title":"Am J Med"},{"key":"BFncpneph0915_CR25","first-page":"347","volume":"62","author":"JF Wetzels","year":"2004","unstructured":"Wetzels JF (2004) Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Neth J Med 62: 347\u2013352","journal-title":"Neth J Med"},{"key":"BFncpneph0915_CR26","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/1097-0142(19921201)70:11<2703::AID-CNCR2820701123>3.0.CO;2-X","volume":"70","author":"ML Meistrich","year":"1992","unstructured":"Meistrich ML et al. (1992) Impact of cyclophosphamide on long-term reduction in sperm count in men treated with combination chemotherapy for Ewing and soft tissue sarcomas. Cancer 70: 2703\u20132712","journal-title":"Cancer"},{"key":"BFncpneph0915_CR27","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.1988.03720140043031","volume":"259","author":"SA Rivkees","year":"1988","unstructured":"Rivkees SA and Crawford JD (1988) The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 259: 2123\u20132125","journal-title":"JAMA"},{"key":"BFncpneph0915_CR28","doi-asserted-by":"crossref","first-page":"R182","DOI":"10.1186\/ar2093","volume":"8","author":"RA Moore","year":"2006","unstructured":"Moore RA and Derry S (2006) Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 8: R182","journal-title":"Arthritis Res Ther"},{"key":"BFncpneph0915_CR29","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"C Ponticelli","year":"1995","unstructured":"Ponticelli C et al. (1995) A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600\u20131604","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/qjmed\/91.5.359","volume":"91","author":"AJ Branten","year":"1998","unstructured":"Branten AJ et al. (1998) Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM 91: 359\u2013366","journal-title":"QJM"},{"key":"BFncpneph0915_CR31","doi-asserted-by":"crossref","unstructured":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61: 1029\u20131037","DOI":"10.1097\/00007890-199604150-00008"},{"key":"BFncpneph0915_CR32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","volume":"353","author":"EM Ginzler","year":"2005","unstructured":"Ginzler EM et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219\u20132228","journal-title":"N Engl J Med"},{"key":"BFncpneph0915_CR33","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","volume":"5","author":"R Robson","year":"2005","unstructured":"Robson R et al. (2005) Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 5: 2954\u20132960","journal-title":"Am J Transplant"},{"key":"BFncpneph0915_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","volume":"185","author":"T Vial","year":"2003","unstructured":"Vial T and Descotes J (2003) Immunosuppressive drugs and cancer. Toxicology 185: 229\u2013240","journal-title":"Toxicology"},{"key":"BFncpneph0915_CR35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2004.11.010","volume":"56","author":"A Andres","year":"2005","unstructured":"Andres A (2005) Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 56: 71\u201385","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFncpneph0915_CR36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.ajkd.2007.05.015","volume":"50","author":"AJ Branten","year":"2007","unstructured":"Branten AJ et al. (2007) Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248\u2013256","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR37","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","volume":"47","author":"DC Cattran","year":"1995","unstructured":"Cattran DC et al. (1995) A controlled trial of cyclosporine in patients with progressive membranous nephropathy: Canadian Glomerulonephritis Study Group. Kidney Int 47: 1130\u20131135","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR38","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC et al. (2001) Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 59: 1484\u20131490","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M et al. (2007) Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 71: 924\u2013930","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR40","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0190-9622(96)90726-4","volume":"35","author":"NJ Lowe","year":"1996","unstructured":"Lowe NJ et al. (1996) Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 35: 710\u2013719","journal-title":"J Am Acad Dermatol"},{"key":"BFncpneph0915_CR41","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/ndt\/gfl360","volume":"21","author":"E Alexopoulos","year":"2006","unstructured":"Alexopoulos E et al. (2006) Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 21: 3127\u20133132","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0915_CR42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/01.tp.0000256179.14038.e2","volume":"83","author":"R Kandaswamy","year":"2007","unstructured":"Kandaswamy R et al. (2007) Stable kidney function in the second decade after kidney transplantation while on cyclosporine-based immunosuppression. Transplantation 83: 722\u2013726","journal-title":"Transplantation"},{"key":"BFncpneph0915_CR43","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","volume":"3","author":"BL Kasiske","year":"2003","unstructured":"Kasiske BL et al. (2003) Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178\u2013185","journal-title":"Am J Transplant"},{"key":"BFncpneph0915_CR44","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/1529-0131(199811)41:11<1930::AID-ART6>3.0.CO;2-N","volume":"41","author":"BE van den Borne","year":"1998","unstructured":"van den Borne BE et al. (1998) No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 41: 1930\u20131937","journal-title":"Arthritis Rheum"},{"key":"BFncpneph0915_CR45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1523-1747.2003.12040.x","volume":"120","author":"CF Paul","year":"2003","unstructured":"Paul CF et al. (2003) Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120: 211\u2013216","journal-title":"J Invest Dermatol"},{"key":"BFncpneph0915_CR46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11255-007-9194-x","volume":"39","author":"H Sheashaa","year":"2007","unstructured":"Sheashaa H et al. (2007) Does cyclosporine achieve a real advantage for treatment of idiopathic nephrotic syndrome in children? A long-term efficacy and safety study. Int Urol Nephrol 39: 923\u2013928","journal-title":"Int Urol Nephrol"},{"key":"BFncpneph0915_CR47","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","volume":"14","author":"P Ruggenenti","year":"2003","unstructured":"Ruggenenti P et al. (2003) Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol 14: 1851\u20131857","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","volume":"73","author":"FC Fervenza","year":"2008","unstructured":"Fervenza FC et al. (2008) Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 73: 117\u2013125","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","volume":"1","author":"P Ruggenenti","year":"2006","unstructured":"Ruggenenti P et al. (2006) Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1: 738\u2013748","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0915_CR50","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","volume":"16","author":"S Troyanov","year":"2005","unstructured":"Troyanov S et al. (2005) Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16: 1061\u20131068","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/ajkd.1998.v32.pm9669427","volume":"32","author":"DC Cattran","year":"1998","unstructured":"Cattran DC and Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32: 72\u201379","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR52","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","volume":"25","author":"JJ Rydel","year":"1995","unstructured":"Rydel JJ et al. (1995) Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 25: 534\u2013542","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR53","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0272-6386(99)70384-7","volume":"34","author":"C Ponticelli","year":"1999","unstructured":"Ponticelli C et al. (1999) Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 34: 618\u2013625","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0272-6386(04)01081-9","volume":"44","author":"C Kitiyakara","year":"2004","unstructured":"Kitiyakara C et al. (2004) Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44: 815\u2013825","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"BFncpneph0915_CR55","first-page":"S37","volume":"35","author":"A Meyrier","year":"1991","unstructured":"Meyrier A et al. (1991) Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 35 (Suppl 1): S37\u2013S42","journal-title":"Clin Nephrol"},{"key":"BFncpneph0915_CR56","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/ki.1993.194","volume":"43","author":"C Ponticelli","year":"1993","unstructured":"Ponticelli C et al. (1993) A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43: 1377\u20131384","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","volume":"7","author":"KV Lieberman","year":"1996","unstructured":"Lieberman KV and Tejani A (1996) A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7: 56\u201363","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR58","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","volume":"56","author":"DC Cattran","year":"1999","unstructured":"Cattran DC et al. (1999) A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis: North America Nephrotic Syndrome Study Group. Kidney Int 56: 2220\u20132226","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR59","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.ki.5002553","volume":"72","author":"DC Cattran","year":"2007","unstructured":"Cattran DC et al. (2007) Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 72: 1429\u20131447","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2215\/CJN.00120605","volume":"1","author":"JA Tumlin","year":"2006","unstructured":"Tumlin JA et al. (2006) A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 1: 109\u2013116","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpneph0915_CR61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1053\/j.ajkd.2006.10.020","volume":"49","author":"ME Cho","year":"2007","unstructured":"Cho ME et al. (2007) Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 49: 310\u2013317","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1523-1755.2004.00834.x","volume":"66","author":"P Simon","year":"2004","unstructured":"Simon P et al. (2004) Epidemiologic data of primary glomerular diseases in western France. Kidney Int 66: 905\u2013908","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR63","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1523-1755.2004.00837.x","volume":"66","author":"LS Li","year":"2004","unstructured":"Li LS and Liu ZH (2004) Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int 66: 920\u2013923","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0272-6386(12)80284-8","volume":"18","author":"E Alamartine","year":"1991","unstructured":"Alamartine E et al. (1991) Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 18: 12\u201319","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR65","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ki.1991.313","volume":"40","author":"S Rekola","year":"1991","unstructured":"Rekola S et al. (1991) Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 40: 1050\u20131054","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR66","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","volume":"18","author":"HN Reich","year":"2007","unstructured":"Reich HN et al. (2007) Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol 18: 3177\u20133183","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR67","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2001.27689","volume":"38","author":"LP Bartosik","year":"2001","unstructured":"Bartosik LP et al. (2001) Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728\u2013735","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR68","first-page":"360","volume":"54","author":"Y Kanno","year":"2000","unstructured":"Kanno Y et al. (2000) Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. Clin Nephrol 54: 360\u2013365","journal-title":"Clin Nephrol"},{"key":"BFncpneph0915_CR69","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N et al. (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117\u2013124","journal-title":"Lancet"},{"key":"BFncpneph0915_CR70","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M et al. (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14: 1578\u20131583","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR71","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo R et al. (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18: 1880\u20131888","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR72","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li PK et al. (2006) Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47: 751\u2013760","journal-title":"Am J Kidney Dis"},{"key":"BFncpneph0915_CR73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"BF Palmer","year":"2004","unstructured":"Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585\u2013592","journal-title":"N Engl J Med"},{"key":"BFncpneph0915_CR74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/00002018-199818030-00003","volume":"18","author":"W Vleeming","year":"1998","unstructured":"Vleeming W et al. (1998) ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 18: 171\u2013188","journal-title":"Drug Saf"},{"key":"BFncpneph0915_CR75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2125.1995.tb04447.x","volume":"39","author":"R Wood","year":"1995","unstructured":"Wood R (1995) Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril: a controlled retrospective cohort study. Br J Clin Pharmacol 39: 265\u2013270","journal-title":"Br J Clin Pharmacol"},{"key":"BFncpneph0915_CR76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0002-9343(94)90172-4","volume":"96","author":"A Shotan","year":"1994","unstructured":"Shotan A et al. (1994) Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 96: 451\u2013456","journal-title":"Am J Med"},{"key":"BFncpneph0915_CR77","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa055202","volume":"354","author":"WO Cooper","year":"2006","unstructured":"Cooper WO et al. (2006) Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354: 2443\u20132451","journal-title":"N Engl J Med"},{"key":"BFncpneph0915_CR78","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM199411033311804","volume":"331","author":"JV Donadio Jr","year":"1994","unstructured":"Donadio JV Jr et al. (1994) A controlled trial of fish oil in IgA nephropathy: Mayo Nephrology Collaborative Group. N Engl J Med 331: 1194\u20131199","journal-title":"N Engl J Med"},{"key":"BFncpneph0915_CR79","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1681\/ASN.V8111739","volume":"8","author":"JJ Dillon","year":"1997","unstructured":"Dillon JJ (1997) Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 8: 1739\u20131744","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR80","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/03655230410003332","volume":"555","author":"H Akagi","year":"2004","unstructured":"Akagi H et al. (2004) Long-term results of tonsillectomy as a treatment for IgA nephropathy. Acta Otolaryngol Suppl 555: 38\u201342","journal-title":"Acta Otolaryngol Suppl"},{"key":"BFncpneph0915_CR81","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1523-1755.2004.00486.x","volume":"65","author":"Y Xie","year":"2004","unstructured":"Xie Y et al. (2004) Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney Int 65: 1135\u20131144","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR82","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mhn.2000.107454","volume":"123","author":"JL Wei","year":"2000","unstructured":"Wei JL et al. (2000) Evaluation of posttonsillectomy hemorrhage and risk factors. Otolaryngol Head Neck Surg 123: 229\u2013235","journal-title":"Otolaryngol Head Neck Surg"},{"key":"BFncpneph0915_CR83","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C et al. (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353: 883\u2013887","journal-title":"Lancet"},{"key":"BFncpneph0915_CR84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C et al. (2004) Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157\u2013163","journal-title":"J Am Soc Nephrol"},{"key":"BFncpneph0915_CR85","doi-asserted-by":"crossref","first-page":"c58","DOI":"10.1159\/000068522","volume":"93","author":"DS Goumenos","year":"2003","unstructured":"Goumenos DS et al. (2003) Prednisolone and azathioprine in IgA nephropathy\u2014a ten-year follow-up study. Nephron Clin Pract 93: c58\u2013c68","journal-title":"Nephron Clin Pract"},{"key":"BFncpneph0915_CR86","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","volume":"68","author":"S Tang","year":"2005","unstructured":"Tang S et al. (2005) Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 68: 802\u2013812","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR87","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes BD et al. (2004) Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65: 1842\u20131849","journal-title":"Kidney Int"},{"key":"BFncpneph0915_CR88","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G et al. (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 20: 2139\u20132145","journal-title":"Nephrol Dial Transplant"},{"key":"BFncpneph0915_CR89","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie FW and Roberts IS (2002) Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13: 142\u2013148","journal-title":"J Am Soc Nephrol"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0915","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:22:33Z","timestamp":1684441353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,26]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["BFncpneph0915"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0915","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,26]]}}}